TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06943950: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT06943950 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06943950 Rescue Dossier →